Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2022
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01FX18
|
| gptkbp:developer |
gptkb:Immunocore
|
| gptkbp:firstBook |
yes
|
| gptkbp:form |
solution for infusion
|
| gptkbp:genericName |
tebentafusp
|
| https://www.w3.org/2000/01/rdf-schema#label |
Kimmtrak
|
| gptkbp:indication |
gptkb:uveal_melanoma
metastatic uveal melanoma unresectable uveal melanoma |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
bispecific T cell engager
redirects T cells to tumor cells targets gp100 protein |
| gptkbp:orphanDrugStatus |
yes
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
fatigue
pruritus rash cytokine release syndrome pyrexia |
| gptkbp:target |
gptkb:CD3
gptkb:gp100 |
| gptkbp:bfsParent |
gptkb:Immunocore
|
| gptkbp:bfsLayer |
6
|